Eden vs. MEDVi: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, MEDVi is the cheaper program at $399 a month all-in versus Eden's $408 — a gap of $9 a month, $108 a year, at the 10 mg maintenance basis. Eden: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. MEDVi: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Prepaid terms reorder things: MEDVi at $249/mo (12-month plan) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, Eden wins at $198 versus $299 all-in — $101/mo apart. Eden: Semaglutide runs $198 a month all-in. MEDVi: Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms).

Transparency

Eden: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. MEDVi: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Eden: membership auto-renews; membership auto-renews until cancelled; $99/mo membership recurs until cancelled. MEDVi: 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

The gap, compounded over time

Here is what the $9 monthly spread between these two actually buys back over a treatment course — one month, $9; six months, $54; a year, $108; two years of maintenance, $216. Only MEDVi publishes a prepaid tier ($249/mo effective), which undercuts even Eden's standing $408 by $1,908/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Maintenance therapies deserve maintenance math: over two years at standing rates, Eden bills $9,792 and MEDVi $9,576, a spread of $216 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, MEDVi's $249 effective would total $5,976 — $3,600 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Eden scales $348 → ~$408 by 10 mg (titration lands between $1,392 and $1,632); MEDVi holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $348 at Eden versus $399 at MEDVi for the 2.5 mg rung — an early edge that reverses once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $4,788/year at MEDVi against $4,896 at the other: $108 of annual daylight for the same molecule and dose. The committed prepayer does best at MEDVi: $249/month effective, $2,988/year, funds up front, refund terms first.

The semaglutide board

The boards split: on semaglutide the order flips, with Eden cheaper at $198 against $299 — a reminder that molecule choice can decide the provider question by itself. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Eden's ranked figure is $408 ($309 medication + $99 mandatory membership); MEDVi's ranked figure is $399, with no membership to add. 2 · Maintenance basis. Eden scales from $348 to $408, and the 10 mg figure is the one ranked; MEDVi is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Eden: standing $408, no prepaid tier; MEDVi: standing $399, prepaid $249 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Eden: source-verified, read 2026-08-05; MEDVi: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Eden names no pharmacy; MEDVi names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Eden: a mandatory $99/mo membership folded into our all-in figure; membership auto-renews until cancelled. MEDVi: no membership — the medication figure is the billed figure; prepaid 12-month plan at $249/mo effective; 12-month plan applies to lowest rate; commitment: 12-month plan for the lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Eden carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. MEDVi carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Eden to MEDVi (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Eden: shipping included; consultation included in membership; async visit model. MEDVi: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Eden if the semaglutide line is cheaper here. Pick MEDVi if the $9/month tirzepatide saving is the point; you want a price that survives titration; you'll prepay for the $249 effective rate; you refuse membership fees on principle. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are Remedy Meds at $399 (flat, no membership); Fridays at $359 (flat, no membership); Lavender Sky Health at $352 (dose-scaled, $25 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $600/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, MEDVi is the cheaper tirzepatide program by $9/mo and it doesn't trade that price for opacity ; Eden's case rests on a cheaper semaglutide line. Both records, with dates and sources, live in the pricing database.